Pacific Edge, a cancer diagnostics company, has announced that test volumes processed in the second quarter of the 2024 financial year fell 12% compared to the previous quarter.
However, the volume of tests processed in Q2 24 increased by 8% compared to the same quarter of the previous year.
The decrease in test volumes was attributed to the reorganization of the company's US operations and uncertainty among physicians and healthcare providers regarding the coverage status of its Cxbladder test.
Test volumes in the US decreased by 15% in Q2 24 compared to the previous quarter, but increased by 9% compared to the same quarter of the previous year.
In the Asia Pacific region, test volumes increased by 10% in Q2 24 compared to the previous quarter and by 2% compared to the same quarter of the previous year.
See more
